Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01850758
Other study ID # RSI2013-RCT01
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 2013
Est. completion date March 8, 2022

Study information

Verified date July 2022
Source Regenexx, LLC
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of this study is to compare the improvement in subject-reported clinical outcomes for Regenexx SD vs. Exercise Therapy treatment of partial and complete, non-retracted knee ACL ligament tears, from baseline to 3 months, with continued evaluation of efficacy and durability up to 24 months. Secondary objectives include evaluation of MRI evidence of tendon repair; incidence of post-operative complications, adverse events, re-injections, and surgical intervention; change in pain score and use of pain medications.


Description:

Prospective, randomized, controlled to include 25 subjects treated with Regenexx SD and 25 subjects treated with exercise therapy alone with the exercise group crossing over to the injection group at 3 months. Subjects will have a partial or complete, non-retracted ACL ligament tear as evidenced with MRI. Subjects will be enrolled within 60 days prior to Regenexx-SD injection or initiation of exercise therapy and take part in follow-up visits for two years following treatment. A preoperative visit will occur at the time of enrollment; follow-up visits will occur at the clinical site at 6 weeks, 3 months, 6 months, 12 months, and 24 months post injection. The primary endpoint analysis will be conducted once all subjects reach the 3 month endpoint. Subjects will continue to be followed through the 2 year endpoint with data analysis performed at the 1 year and 2 year time points.


Recruitment information / eligibility

Status Completed
Enrollment 50
Est. completion date March 8, 2022
Est. primary completion date May 22, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Pain, swelling, or functional disability in the affected knee with activity, having failed conservative treatment (e.g. NSAIDs, physician initiated physical therapy) for at least 3 months or unable to return to normal day to day activities by 6 weeks - Physical examination consistent with lax ACL ligament (Anterior Drawer Test) - Abnormal Telos Arthrometer measurement - Positive diagnostic MR imaging of the affected knee with at least 1/3 of the ACL ligament at any area along its length having high signal on MRI PDFS/Fat Sat images. - Full range of motion of the affected knee (other than restriction clearly due to effusion) - Normal range of motion of the non-treated knee - Is independent, ambulatory, and can comply with all post-operative evaluations and visits Exclusion Criteria: - A massive ACL tear or one that includes more than 2/3'rds of the ligament that's retracted. - Previous surgery to the affected ACL (i.e. previous ACL replacement with an autograft or allograft) - Prior ACL prolotherapy, PRP, corticosteroid injection or other injection therapy within the past three months, - Concomitant meniscus tear or cartilage injury that occurred at the same time as the as the ACL tear and which is considered a pain generator by the treating physician at the time intake into the study (i.e. a meniscus tear or cartilage lesion associated with an active BML). - Concomitant PCL or LCL tears - Inflammatory or auto-immune based joint diseases or other lower extremity pathology (e.g., rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, polymyalgia, polymyositis, gout pseudogout) - Quinolone or Statin induced myopathy/ tendinopathy - Kellgren-Lawrence grade 2 or greater knee osteoarthritis - Significant knee extension lag compared to the opposite knee - Symptomatic lumbar spine pathology (e.g. radicular pain) - Severe neurogenic inflammation of the cutaneous nerves about the knee or thigh - Contraindications for MRI - Tested positive or has been treated for a malignancy in the past or is suspected of having a malignancy or is currently undergoing radiation or chemotherapy treatment for a malignancy anywhere in the body, whether adjacent to or distant from the proposed injection site - Condition represents a worker's compensation case - Currently involved in a health-related litigation procedure - Is pregnant - Bleeding disorders - Currently taking anticoagulant or immunosuppressive medication - Allergy or intolerance to study medication - Use of chronic opioid,

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Regenexx SD
stem cell treatment
Other:
Exercise Therapy
exercise therapy control

Locations

Country Name City State
United States Centeno-Schultz Clinic Broomfield Colorado

Sponsors (1)

Lead Sponsor Collaborator
Regenexx, LLC

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary IKDC Subjective Knee Evaluation Score Change from Baseline The primary endpoint for this study is the difference between treatment groups in the within patient mean change from baseline to 3 months in IKDC scores. Change from Baseline to 3 months
Secondary Mean Pain Scales Difference between treatment groups in mean 0-10 pain scales at each follow-up timepoint 3, 6, 12 and 24 months
Secondary Magnetic Resonance Evaluation of ligament repair Comparison of Magnetic Resonance Evaluation of ligament repair at 6 months 6 months
Secondary Mean IKDC Subjective Knee Evaluation Scores Difference between treatment groups in mean KDC Subjective Knee Evaluation Scores at 6, 12 and 24 months. 6, 12 and 24 months
Secondary Incidence of complications and adverse events Incidence and time to resolution of post-operative complications and adverse events between treatment groups. 24 months
Secondary Incidence of re-injection and surgical revision Incidence of and time to re-injection and surgical revision between treatment groups. 24 months
Secondary Use of pain medications Difference between treatment groups in use of pain medications at each follow-up timepoint 3, 6, 12 and 24 months
See also
  Status Clinical Trial Phase
Completed NCT05109871 - Reliability and Validity of Inline Dynamometry Study for Measuring Knee Extensor Torque N/A
Recruiting NCT04088227 - Effects of Platelet Rich Plasma Injections on Biomarkers After Anterior Cruciate Ligament Tears Phase 2
Completed NCT04956393 - The SOAR (Stop OsteoARthritis) Program Proof-of-Concept Study N/A
Recruiting NCT05574946 - Comparison of Two ACL Reconstruction Techniques: All-inside Versus Complete Tibial Tunnel Technique N/A
Completed NCT01447277 - Prospective Femoral Versus Femoral and Sciatic Nerve Block for Anterior Cruciate Ligament (ACL) Reconstruction N/A
Recruiting NCT06430775 - Exploring Prolonged AMR in ACL Reconstructed Patients
Terminated NCT02911909 - Moderated Blood Flow Restriction After Anterior Cruciate Ligament Reconstruction N/A
Completed NCT02760589 - Magnetic Resonance Imaging and Functional Performance Outcome After ACL Repair With Internal Brace Technique
Completed NCT02787096 - Dynamic Knee Laxity Measurement Coupled to MRI in Cases of Suspected Partial Anterior Cruciate Ligament Tear N/A
Completed NCT04635579 - Personalized Blood Flow Restriction for Anterior Cruciate Ligament Rehabilitation N/A
Recruiting NCT05204836 - Altering Bone Microarchitecture and Mechanics by Off-label Pharmaceutical Intervention Following an Acute Knee Injury Phase 1
Recruiting NCT04592471 - Assessment of the Safety and Performance of Knee Ligament Supports in the Context of a Return to Sport After Sprain
Completed NCT01580722 - Comparison of Early Versus Delay Reconstruction in Anterior Cruciate Ligament Tearing Phase 2
Recruiting NCT05174611 - Vitamin D to Improve Quadricep Muscle Strength Phase 2
Recruiting NCT05501210 - Vibration on Patellofemoral Joint Pain After ACLR N/A
Recruiting NCT05682820 - Analysis of Radiological Features of Lateral Femoral Impaction Fracture / Lateral Femoral Notch Sign
Terminated NCT02930122 - IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions Phase 2
Recruiting NCT05306054 - Physical Activity, Knee Joint Loading and Joint Health
Completed NCT04374968 - Use of Blood Flow Restriction Therapy Following ACL Tear N/A
Recruiting NCT04998656 - Werewolf Flow 50 During ACL Reconstruction N/A